<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0001-6002</journal-id>
<journal-title><![CDATA[Acta Médica Costarricense]]></journal-title>
<abbrev-journal-title><![CDATA[Acta méd. costarric]]></abbrev-journal-title>
<issn>0001-6002</issn>
<publisher>
<publisher-name><![CDATA[Colegio de Médicos y Cirujanos de Costa Rica]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0001-60022019000200073</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Usos, contexto regulatorio y ético de la talidomida en Costa Rica]]></article-title>
<article-title xml:lang="en"><![CDATA[Thalidomide in Costa Rica: uses, regulatory and ethical context]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rivera-Chavarría]]></surname>
<given-names><![CDATA[Ana]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Espinoza-Aguirre]]></surname>
<given-names><![CDATA[Azálea]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Instituto Costarricense de Investigación y Enseñanza en Nutrición y Salud (INCIENSA) Unidad Salud y Nutrición ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
</aff>
<aff id="Af2">
<institution><![CDATA[,Ministerio de Salud Dirección de Vigilancia de la Salud ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Costa Rica</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>06</month>
<year>2019</year>
</pub-date>
<volume>61</volume>
<numero>2</numero>
<fpage>73</fpage>
<lpage>76</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_arttext&amp;pid=S0001-60022019000200073&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_abstract&amp;pid=S0001-60022019000200073&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.sa.cr/scielo.php?script=sci_pdf&amp;pid=S0001-60022019000200073&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen En las últimas décadas, el descubrimiento de las propiedades antinflamatorias, antiangiogénicas e inmunorreguladoras de la talidomida, ha propiciado su utilización como terapia alternativa o de segunda elección para diversas patologías. El medicamento forma parte de la Lista Oficial de Medicamentos y Normativa de la Caja Costarricense de Seguro Social. El resurgimiento del medicamento y sus análogos, los cambios en el comportamiento reproductivo de la población, avances en las técnicas de reproducción asistida, investigación biomédica y la judicialización de la medicina, hacen necesaria una revisión de sus indicaciones actuales, y medidas de seguridad para prevenir el efecto adverso más grave: la teratogénesis. El objetivo de esta investigación fue presentar los resultados de una revisión bibliográfica relacionada con los usos actuales, así como el contexto regulatorio y ético de la talidomida en Costa Rica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract In recent decades, thalidomide´s anti-inflammatory, anti-angiogenic and immunoregulatory properties have led as an alternative or second-choice therapy for various pathologies. It is currently included in the Official List of Medicines and Regulations of the Costa Rican Social Security (LOM). However, thalidomide´s resurgence and its analogues, reproductive behavior changes, assisted reproduction technology, biomedical research and medical judicialization, indicates that a review of the current indications and safety measures are necessary to prevent the most serious adverse effect: teratogenesis. In this research, we aim to summarize thalidomide´s current uses, regulatory and ethical context in Costa Rica.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[talidomida]]></kwd>
<kwd lng="es"><![CDATA[IMiDS]]></kwd>
<kwd lng="es"><![CDATA[aspectos éticos]]></kwd>
<kwd lng="es"><![CDATA[regulación]]></kwd>
<kwd lng="en"><![CDATA[Thalidomide]]></kwd>
<kwd lng="en"><![CDATA[IMiDS]]></kwd>
<kwd lng="en"><![CDATA[ethical issues]]></kwd>
<kwd lng="en"><![CDATA[regulation]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ordi-Ros]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Cosiglio]]></surname>
<given-names><![CDATA[FJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Indicaciones terapéuticas actuales de la talidomida y la lenalidomida]]></article-title>
<source><![CDATA[Med Clin (Barc)]]></source>
<year>2014</year>
<volume>142</volume>
<page-range>360-4</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vargesson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thalidomide-induced teratogenesis History and mechanisms.]]></article-title>
<source><![CDATA[Birth Defects Res C Embryo Today]]></source>
<year>2015</year>
<volume>105</volume>
<page-range>140-56</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papaseit]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[García-Algar]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Farré]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Talidomida una historia inacabada]]></article-title>
<source><![CDATA[An Pediatr (Barc)]]></source>
<year>2013</year>
<volume>78</volume>
<page-range>283-7</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rehman]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Arfons]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Lazarus]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The Rise, Fall and Subsequent Triumph of Thalidomide Lessons Learned in Drug Development]]></article-title>
<source><![CDATA[Ther Adv Hematol.]]></source>
<year>2011</year>
<volume>2</volume>
<page-range>291-308</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[JH]]></given-names>
</name>
<name>
<surname><![CDATA[Scialli]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thalidomide The Tragedy of Birth Defects and the Effective Treatment of Disease]]></article-title>
<source><![CDATA[Toxicol Sci.]]></source>
<year>2011</year>
<volume>122</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shortt]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hsu]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Johnstone]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thalidomide-analogue biology immunological, molecular and epigenetic targets in cancer therapy]]></article-title>
<source><![CDATA[Oncogene.]]></source>
<year>2013</year>
<volume>32</volume>
<page-range>4191-202</page-range></nlm-citation>
</ref>
<ref id="B7">
<nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Deng]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Ding]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Granstein]]></surname>
<given-names><![CDATA[RD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thalidomide Inhibits Tumor Necrosis Factor-a Production and Antigen Presentation by Langerhans Cells]]></article-title>
<source><![CDATA[J Invest Dermatol.]]></source>
<year>2003</year>
<volume>121</volume>
<page-range>1060-5</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<collab>CCSS</collab>
<source><![CDATA[Lista Oficial de Medicamentos 2018]]></source>
<year>2018</year>
<publisher-loc><![CDATA[San José ]]></publisher-loc>
<publisher-name><![CDATA[Caja Costarricense de Seguro Social;]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Keifer]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Guttridge]]></surname>
<given-names><![CDATA[DC]]></given-names>
</name>
<name>
<surname><![CDATA[Ashburner]]></surname>
<given-names><![CDATA[BP]]></given-names>
</name>
<name>
<surname><![CDATA[Baldwin]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity]]></article-title>
<source><![CDATA[J Biol Chem]]></source>
<year>2001</year>
<volume>276</volume>
<page-range>22382-7</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[T-C]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[Wu]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thalidomide-a notorious sedative to a wonder anticancer drug]]></article-title>
<source><![CDATA[Curr Med Chem]]></source>
<year>2013</year>
<volume>20</volume>
<page-range>4102-8</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Millrine]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kishimoto]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A Brighter Side to Thalidomide Its Potential Use in Immunological Disorders]]></article-title>
<source><![CDATA[Trends Mol Med.]]></source>
<year>2017</year>
<volume>23</volume>
<page-range>348-61</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ogura]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Hotta]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Imamura]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Identification of a primary target of thalidomide teratogenicity]]></article-title>
<source><![CDATA[Science]]></source>
<year>2010</year>
<volume>327</volume>
<page-range>1345-50</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stephens]]></surname>
<given-names><![CDATA[TD]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Proposed mechanisms of action in thalidomide embryopathy]]></article-title>
<source><![CDATA[Teratology]]></source>
<year>1988</year>
<volume>38</volume>
<page-range>229-39</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mori]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Ito]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Ando]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Sakamoto]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Yamaguchi]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Structural basis of thalidomide enantiomer binding to cereblon]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2018</year>
<volume>8</volume>
<page-range>1294</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Guo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Zhu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[He]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Xie]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thalidomide and its analogues A review of the potential for immunomodulation of fibrosis diseases and opthalmopathy.]]></article-title>
<source><![CDATA[Exp Ther Med]]></source>
<year>2017</year>
<volume>14</volume>
<page-range>5251-7</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Quach]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Ritchie]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Stewart]]></surname>
<given-names><![CDATA[AK]]></given-names>
</name>
<name>
<surname><![CDATA[Neeson]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Harrison]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Smyth]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mechanism of action of immunomodulatory drugs (IMiDS) in multiple myeloma]]></article-title>
<source><![CDATA[Leukemia]]></source>
<year>2010</year>
<volume>24</volume>
<page-range>22-32</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fink]]></surname>
<given-names><![CDATA[EC]]></given-names>
</name>
<name>
<surname><![CDATA[Ebert]]></surname>
<given-names><![CDATA[BL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The novel mechanism of lenalidomide activity]]></article-title>
<source><![CDATA[Blood.]]></source>
<year>2015</year>
<volume>126</volume>
<page-range>2366-9</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[von Lilienfeld-Toal]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn-Ast]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Furkert]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Hoffmann]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Naumann]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Bargou]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma]]></article-title>
<source><![CDATA[Eur J Haematol]]></source>
<year>2008</year>
<volume>81</volume>
<page-range>247-52</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Beedie]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
<name>
<surname><![CDATA[Mahony]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Walker]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Chau]]></surname>
<given-names><![CDATA[CH]]></given-names>
</name>
<name>
<surname><![CDATA[Figg]]></surname>
<given-names><![CDATA[WD]]></given-names>
</name>
<name>
<surname><![CDATA[Vargesson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Shared mechanism of teratogenicity of anti-angiogenic drugs identified in the chicken embryo model]]></article-title>
<source><![CDATA[Sci Rep]]></source>
<year>2016</year>
<volume>6</volume>
<page-range>30038</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Clark]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Steinbach]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Clemmons]]></surname>
<given-names><![CDATA[AB]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Pomalidomide for the Treatment of Multiple Myeloma]]></article-title>
<source><![CDATA[J Adv Pract Oncol]]></source>
<year>2014</year>
<volume>5</volume>
<page-range>51-6</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eltonsy]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Martin]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Ferreira]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Blais]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Systematic procedure for the classification of proven and potential teratogens for use in research]]></article-title>
<source><![CDATA[Birth Defects Res A Clin Mol Teratol]]></source>
<year>2016</year>
<volume>106</volume>
<page-range>285-97</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gallego Úbeda]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Delgado Téllez de Cepeda]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Campos Fernández de Sevilla]]></surname>
<given-names><![CDATA[MdlA]]></given-names>
</name>
<name>
<surname><![CDATA[Lorenzo Pinto]]></surname>
<given-names><![CDATA[Ad]]></given-names>
</name>
<name>
<surname><![CDATA[Tutau Gómez]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización del uso de fármacos durante el embarazo categorías de riesgo]]></article-title>
<source><![CDATA[Farm Hosp]]></source>
<year>2014</year>
<volume>38</volume>
<page-range>364-78</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lau]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Choudhury]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Assaf]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Laskin]]></surname>
<given-names><![CDATA[OL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distribution of lenalidomide into semen of healthy men after multiple oral doses]]></article-title>
<source><![CDATA[J Clin Pharmacol]]></source>
<year>2010</year>
<volume>50</volume>
<page-range>767-74</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Liu]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Reyes]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Palmisano]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Distribution of pomalidomide into semen of healthy male subjects after multiple doses]]></article-title>
<source><![CDATA[Clin Pharmacol]]></source>
<year>2018</year>
<volume>10</volume>
<page-range>53-62</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gordon]]></surname>
<given-names><![CDATA[JN]]></given-names>
</name>
<name>
<surname><![CDATA[Goggin]]></surname>
<given-names><![CDATA[PM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Thalidomide and its derivatives emerging from the wilderness]]></article-title>
<source><![CDATA[Postgrad Med J]]></source>
<year>2003</year>
<volume>79</volume>
<page-range>127</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zeldis]]></surname>
<given-names><![CDATA[JB]]></given-names>
</name>
<name>
<surname><![CDATA[Williams]]></surname>
<given-names><![CDATA[BA]]></given-names>
</name>
<name>
<surname><![CDATA[Thomas]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Elsayed]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[S T.E.P.S.: a comprehensive program for controlling and monitoring access to thalidomide]]></article-title>
<source><![CDATA[Clin Ther]]></source>
<year>1999</year>
<volume>21</volume>
<page-range>319-30</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bwire]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Freeman]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Houn]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Managing the teratogenic risk of thalidomide and lenalidomide an industry perspective]]></article-title>
<source><![CDATA[Expert Opin Drug Saf]]></source>
<year>2011</year>
<volume>10</volume>
<page-range>3-8</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Paumgartten]]></surname>
<given-names><![CDATA[FJR]]></given-names>
</name>
<name>
<surname><![CDATA[Souza]]></surname>
<given-names><![CDATA[NRd]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Clinical use and control of the dispensing of thalidomide in Brasilia-Federal District, Brazil, from 2001 to 2012]]></article-title>
<source><![CDATA[Cien Saude Colet]]></source>
<year>2013</year>
<volume>18</volume>
<page-range>3401-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[No role for thalidomide in the treatment of leprosy]]></article-title>
<source><![CDATA[J Infect Dis.]]></source>
<year>2006</year>
<volume>193</volume>
<page-range>1743-4</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Crawford]]></surname>
<given-names><![CDATA[CL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Treatment of erythema nodosum leprosum with thalidomide]]></article-title>
<source><![CDATA[Lancet]]></source>
<year>1973</year>
<volume>2</volume>
<page-range>567-8</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Haslett]]></surname>
<given-names><![CDATA[PAJ]]></given-names>
</name>
<name>
<surname><![CDATA[Kaplan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Reply to Crawford]]></article-title>
<source><![CDATA[J Infect Dis]]></source>
<year>2006</year>
<volume>193</volume>
<page-range>1744-5</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
